Latest News

Tuesday, October 23, 2018

LA BioMed Team to Study Treatments for Antibiotic-Resistant Skin Infections

Investigators from LA BioMed have scored a $5.3M grant from the National Institutes of Health to study the effectiveness of treatments for antibiotic-resistant skin infections. The study, Short and…

Read the full story

Tuesday, October 23, 2018

Ilumya Now Available for Moderate-to-Severe Plaque Psoriasis

Ilumya™ (tildrakizumab-asmn) 100mg/mL from Sun Pharmaceutical Industries Ltd. is now available in the United States. Ilumya is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA …

Read the full story

Tuesday, October 23, 2018

Almirall, LLC is the New Name of Aqua

Almirall, LLC is the new name of Aqua Pharmaceuticals. Almirall, LLC is part of the larger Almirall, S.A. family, an internationally-recognized global dermatology pharmaceutical company, wit…

Read the full story

Monday, October 22, 2018

Opdivo Plus Yervoy Demonstrates Durable Four-Year Survival Benefits in Advanced Melanoma

Four-year data from the Phase 3 CheckMate-067 clinical trial -- the longest follow-up to date -- continue to demonstrate durable, long-term survival benefits with the first-line combination of Op…

Read the full story

Monday, October 22, 2018

New from xMedica: Aesthetics Conference Features Energy Based Treatments for Male and Female Sexual Wellness

Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding g…

Read the full story

Thursday, October 18, 2018

Residents of Distinction Attend 2018 Coastal Dermatology Symposium

As part of the dermMentors Resident of Distinction Award program, sponsored by Beiersdorf Inc., five dermatology residents attended the 14th Annual Coastal Dermatology Symposium, held i…

Read the full story

Thursday, October 18, 2018

Amgevita, Amgen's Biosimilar Adalimumab, Launches in Europe

Amgen's Amgevita, a biosimilar to adalimumab, has launched in markets across Europe. Amgevita is the first adalimumab biosimilar to be approved by the European Commission …

Read the full story

Thursday, October 18, 2018

Paradigm Shift: Cancer Patients Can Now Use Skin Creams During Radiation Therapy

Contrary to the advice most cancer patients receive when they go through radiation treatment, topical skin treatments, unless applied very heavily, do not increase the radiation dose to the skin and c…

Read the full story

Thursday, October 18, 2018

Almirall’s Seysara Set to Shake Up US Acne Market

The US Food and Drug Administration’s approval of Almirall’s Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients age…

Read the full story

Wednesday, October 17, 2018

New from Lumenis: NuEra Tight Radio Frequency Device

Lumenis has launched NuEra tight, a  non-invasive, intelligent temperature-controlled technology for both superficial and deep heating that treats a variety of conditions, suc…

Read the full story

Wednesday, October 17, 2018

Psoriasis Plus Hypertension Equals Greater Need for Heart Surgery

Patients with psoriasis and hypertension need more cardiovascular procedures and surgeries than hypertensive patients without psoriasis, a new study in the Journal of Dermatology suggests. In 5.62 …

Read the full story

Wednesday, October 17, 2018

Real-world Evaluation Study Confirms Benefits of ARTAS iX Robotic Hair Restoration System

Restoration Robotics, Inc. (NASDAQ: HAIR), the global leader in robotic hair restoration, today announced results from a real-world evaluation study. The new ARTAS iX™ Robotic Hair Restoratio…

Read the full story

Wednesday, October 17, 2018

Aclaris Acquires Rhofade from Allergan

Aclaris Therapeutics, Inc. has entered into a definitive asset purchase agreement with Allergan Sales, LLC to acquire worldwide rights to Rhofade® (oxymetazoline hydrochloride) cream, 1% and addit…

Read the full story

Monday, October 15, 2018

Krystal Biotech: Positive Interim Results in Phase 1/2 Trial of KB103

Krystal Biotech, Inc. has announced positive interim results from its ongoing placebo-controlled Phase 1/2 clinical trial of KB103. Two adult Recessive Dystrophic Epidermolysis Bullosa (“RDEB…

Read the full story

Monday, October 15, 2018

Lumenis Introduces SPLENDOR X, New Laser Hair Removal Solution

Lumenis Ltd. has launched SPLENDOR X, the first solid state laser system equipped with the unique BLEND X technology for fast and effective hair removal and skin solutions. The technology was showcase…

Read the full story
Load More